(Reuters) - The acquisition, announced on Monday, is the boldest move yet by Chief Executive David Brennan, who has been seeking to bolster the company's drug portfolio following a series of product setbacks.
AstraZeneca said the agreed, all-cash deal, which was reported earlier by a source close to the situation, was expected to close in June 2007.
Read more at Reuters.com Business News
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment